Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10‐month withdrawal of pioglitazone in patients with Type 2 diabetes. Issue 11 (30th May 2014)

• Record Type: Journal Article
• Authors: Lin, K.‐D.; Lee, M.‐Y.; Feng, C.‐C.; Chen, B. K.; Yu, M.‐L.; Shin, S.‐J.
• Is Part Of: Diabetic medicine. Volume 31:Issue 11(2014:Nov.)
• Page Start: 1341
• Page End: 1349
• Publication Date: 2014-05-30
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.12481
• Languages: English
• ISSNs: 0742-3071

Abstract

<abstract abstract-type="main" id="dme12481-abs-0001"> <title>Abstract</title> <sec id="dme12481-sec-0001" sec-type="section"> <title>Aim</title> <p>To investigate the recovery of thiazolidinedione‐induced body weight gain and haematopoietic changes after stopping pioglitazone treatment in patients with Type 2 diabetes.</p> </sec> <sec id="dme12481-sec-0002" sec-type="section"> <title>Methods</title> <p>This retrospective cohort study included 214 patients divided into three groups according to pioglitazone treatment status. The first study arm included patients who received pioglitazone for 38 months then interrupted this for 10 months (pioglitazone‐interruption group). The second arm consisted of patients who received pioglitazone throughout the 48 months (pioglitazone‐continuous group); the third arm included patients who had never received pioglitazone therapy (control group).</p> </sec> <sec id="dme12481-sec-0003" sec-type="section"> <title>Results</title> <p>Red blood cell count and haematocrit and haemoglobin levels decreased significantly, while body weight increased in the two pioglitazone‐treated groups as compared with the control group at 38 months. Multivariate regression analysis showed that the reductions in red blood cell count/haemoglobin levels were associated with pioglitazone use. In the pioglitazone‐interruption group, no recoveries of red blood cells, or haematocrit or haemoglobin levels were observed after stopping pioglitazone for 10 months compared with the pioglitazone‐continuous group, but body weight gain decreased to a level that was significantly lower than that in the pioglitazone‐continuous group and did not differ significantly from the control group.</p> </sec> <sec id="dme12481-sec-0004" sec-type="section"> <title>Conclusion</title> <p>In this study, we observed a reversal of body weight gain but no recoveries in red blood cells or haematocrit or haemoglobin levels after stopping pioglitazone for 10 months in patients treated with pioglitazone for 38 months. This finding should prompt a reconsideration of the sustained effect of thiazolidinediones on the haematopoietic system in patients with Type 2 diabetes.</p> </sec> </abstract>